Table 7.6i
Immunosuppression Use for Antirejection Treatment from Transplant to One Year Following Transplantation, 1995 to 2004
Recipients with Pancreas After Kidney (PAK) Transplants

	Year of Transplant									
	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Transplants	67	113	130	156	220	304	305	375	344	420
Tx with Antirejection Treatments	25	38	41	44	57	65	45	43	61	59
Antibodies										
Any in Category	64.0%	76.3%	61.0%	59.1%	75.4%	53.8%	60.0%	48.8%	65.6%	59.3%
ALG	16.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	8.0%	13.2%	17.1%	9.1%	1.8%	1.5%	2.2%	0.0%	3.3%	0.0%
OKT3	48.0%	68.4%	51.2%	45.5%	63.2%	35.4%	26.7%	25.6%	13.1%	15.3%
Thymoglobulin	0.0%	0.0%	0.0%	2.3%	22.8%	21.5%	33.3%	30.2%	45.9%	44.1%
Zenapax	0.0%	0.0%	0.0%	2.3%	1.8%	1.5%	2.2%	2.3%	6.6%	0.0%
Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	4.6%	4.4%	0.0%	4.9%	0.0%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	27.9%	8.5%
Corticosteroids										
Any in Category	48.0%	65.8%	78.0%	70.5%	84.2%	87.7%	86.7%	90.7%	68.9%	79.7%
Steroids	48.0%	65.8%	78.0%	70.5%	84.2%	87.7%	86.7%	90.7%	68.9%	79.7%
Antimetabolites										
Any in Category	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.